logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
arrow
D

David R. Spigel

roche holding usa
H-index:97
Citation Count:7.7万
Views:0

Biography

No content for now.

Education

No content for now.

Work Experience

No content for now.

Honors & Awards

No content for now.

Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial

社区招募和包容性举措对基于生物标志物的MyTACTIC试验入组的影响

FUTURE ONCOLOGY
IF2.6
2025-12-010
PRE
Zuniga, Richard M.; Vanderwalde, Ari; Schwartzberg, Lee S.; Spigel, David R.; Passler, Luke; Hong, Jason; Howland, Michael; Darbonne, Walter C.; Szado, Tania; Daniel, Davey
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up

替雷利珠单抗 + 化疗在胃癌中的应用：长期RATIONALE-305随机试验随访

Advances in Therapy
IF4
2025-11-180
OAAI
Marcia Cruz-Correa; Do-Youn Oh; Ken Kato; Josep Tabernero; Yuxian Bai; Jianhua Shi; Keun-Wook Lee; Hidekazu Hirano; David Spigel; Lucjan Wyrwicz; Roberto Pazo Cid; Antonio Cubillo Gracián; Yaling Xu; Tao Sheng; Silu Yang; Rui-Hua Xu; Markus Moehler
Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer

阿达沃塞替布（Adavosertib，一种Wee1抑制剂）联合多西他赛或卡铂联合培美曲塞治疗非小细胞肺癌的II期临床试验两例。

Targeted Oncology
IF4
2025-11-100
OAAI
Melissa L. Johnson; Shaker R. Dakhil; J. Thaddeus Beck; Ahad Sadiq; Smitha Menon; Ganesh M. Mugundu; Juliann Chmielecki; David R. Spigel
Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials

数字与人工PD-L1评分在晚期非小细胞肺癌中的应用比较：基于IMpower110和IMpower150试验

Journal of Thoracic Oncology
IF20.8
2025-08-050
PRE
Roy S. Herbst; Hen Prizant; Daniel Ruderman; Jake Conway; John Shamshoian; Hartmut Koeppen; Wei Zou; Filippo de Marinis; Giuseppe Giaccone; Jacek Jassem; David R. Spigel; Mark A. Socinski; Martin Reck; Luciana Molinero; Marcus Ballinger; David Shames; Michael Griffin; Limin Yu; Nishant Agrawal; Andrew Beck; Ilan Wapinski; Stephanie Hennek; Jennifer Giltnane; Minu K. Srivastava
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial

根据14基因表达谱被鉴定为分子高危的IA–IIA期非鳞状、非小细胞肺癌的辅助化疗（AIM-HIGH）：一项国际、随机、III期临床试验

The Lancet Respiratory Medicine
IF0
2025-06-240
OAAI
David R Spigel; Virginie Westeel; Ian C Anderson; Laurent Greillier; Florian Guisier; Olivier Bylicki; Firas B Badin; Gaelle Rousseau-Bussac; Clotilde Deldycke; Frank Griesinger; Adam Bograd; Wangjian Zhong; Jacques Le Treut; Sylvie Van Hulst; David R Gandara; Martin Reck; Petra Hoffknecht; Matthew A Gubens; John Crowley; Heiko von der Leyen; Gavitt A Woodard; David M Jablons; Johannes R Kratz; Michael J Mann
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

循环肿瘤DNA监测和接受阿特珠单抗治疗的转移性实体瘤患者的血液肿瘤突变负荷

MOLECULAR ONCOLOGY
IF4.5
2025-05-280
OAAI
Charles Swanton; Russell W. Madison; Candice Francheska B. Tambaoan; Funda Meric-Bernstam; Christopher J. Sweeney; Razelle Kurzrock; Howard A. Burris III; David R. Spigel; Hanna Tukachinsky; Jason Hughes; Julia Malato; Bongin Yoo; Tania Szado; Cheryl Schwab; Lincoln W. Pasquina; Amaya Gasco; Katja Schulze; Claire F. Friedman
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的晚期胃癌: 原理305的回顾性分析

ADVANCES IN THERAPY
IF4
2025-03-010
OAAI
Moehler, Markus; Oh, Do-Youn; Kato, Ken; Arkenau, Tobias; Tabernero, Josep; Lee, Keun-Wook; Rha, Sun Young; Hirano, Hidekazu; Spigel, David; Yamaguchi, Kensei; Wyrwicz, Lucjan; Disel, Umut; Pazo-Cid, Roberto A.; Fornaro, Lorenzo; Xu, Yaling; Sheng, Tao; Yang, Silu; Kadva, Alysha; Cruz-Correa, Marcia; Xu, Rui-Hua
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors
TARGETED ONCOLOGY
IF4
2024-11-190
OAAI
Patel, Manish R.; Falchook, Gerald S.; Wang, Judy S.; Imedio, Esteban Rodrigo; Kumar, Sanjeev; Miah, Kowser; Mugundu, Ganesh M.; Jones, Suzanne F.; Spigel, David R.; Hamilton, Erika P.
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial
TARGETED ONCOLOGY
IF4
2024-11-011
OAAI
Hamilton, Erika P.; Falchook, Gerald S.; Wang, Judy S.; Fu, Siqing; Oza, Amit M.; Imedio, Esteban Rodrigo; Kumar, Sanjeev; Ottesen, Lone; Mugundu, Ganesh M.; de Bruin, Elza C.; O'Connor, Mark J.; Jones, Suzanne F.; Spigel, David R.; Li, Bob T.
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

局限期小细胞肺癌放化疗后的Durvalumab

NEW ENGLAND JOURNAL OF MEDICINE
IF78.5
2024-10-108
PRE
Cheng, Ying; Spigel, David R.; Cho, Byoung Chul; Laktionov, Konstantin K.; Fang, Jian; Chen, Yuanbin; Zenke, Yoshitaka; Lee, Ki Hyeong; Wang, Qiming; Navarro, Alejandro; Bernabe, Reyes; Buchmeier, Eva Lotte; Chang, John Wen-Cheng; Shiraishi, Yoshimasa; Goksu, Sema Sezgin; Badzio, Andrzej; Shi, Anhui; Daniel, Davey B.; Hoa, Nguyen Thi Thai; Zemanova, Milada; Mann, Helen; Gowda, Hema; Jiang, Haiyi; Senan, Suresh
Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results

奥潘奈克立定（RGX-202-01）的Ib/II期研究，奥潘奈克立定是一种首创口服型肌酸转运蛋白SLC6A8抑制剂，该研究联合FOLFIRI和贝伐珠单抗（BEV）用于RAS突变（RASmt）二线（2L）晚期/转移性结直肠癌（mCRC）的更新结果

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Hendifar, A.; Gong, J.; Spigel, D. R.; Basu-Mallick, A.; Espinosa, A.; Misleh, J. G.; Richards, D.; Boles, J.; Fakih, M.; Paulson, A. S.; Chung, K.; Cohn, A.; Gupta, M.; Johnson, K.; Bechar, N.; Hoffman, K. A.; Spector, S.; Szarek, M.; Wasserman, R.; Rosen, L. S.
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up

替雷利珠单抗（TIS）联合化疗（CT）对比安慰剂（PBO）联合化疗（CT）治疗HER2阴性晚期或转移性胃或胃食管结合部腺癌（GC/GEJC）：RATIONALE-305研究至少3年生存随访

ANNALS OF ONCOLOGY
IF65.4
2024-09-014
PRE
Cruz-Correa, M.; Oh, D-Y.; Kato, K.; Tabernero, J.; Bai, Y.; Shi, J.; Lee, K-W.; Hirano, H.; Spigel, D. R.; Wyrwicz, L. S.; Pazo Cid, R. A.; Cubillo Gracian, A.; Li, L.; Xu, Y.; Sheng, T.; Yang, S.; Xu, R-H.; Moehler, M.
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab加化疗与安慰剂加化疗作为晚期胃或胃食管交界处腺癌的一线治疗: 原理305的随机，双盲，3期试验

BMJ-BRITISH MEDICAL JOURNAL
IF42.7
2024-05-2810
OA
Qiu, Miao-Zhen; Oh, Do-Youn; Kato, Ken; Arkenau, Tobias; Tabernero, Josep; Correa, Marcia Cruz; Zimina, Anastasia, V; Bai, Yuxian; Shi, Jianhua; Lee, Keun-Wook; Wang, Jufeng; Poddubskaya, Elena; Pan, Hongming; Rha, Sun Young; Zhang, Ruixing; Hirano, Hidekazu; Spigel, David; Yamaguchi, Kensei; Chao, Yee; Wyrwicz, Lucjan; Disel, Umut; Cid, Roberto Pazo; Fornaro, Lorenzo; Evesque, Ludovic; Wang, Hongwei; Xu, Yaling; Li, Jiang; Sheng, Tao; Yang, Silu; Li, Liyun; Moehler, Markus; Xu, Rui-Hua
A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in triple negative breast cancer and transcriptionally addicted relapsed or refractory solid tumors
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Mita, Monica; Mita, Alain; Villalona-Calero, Miguel; Federman, Noah; Rasco, Drew; Spigel, David; Luo, Jia; Cote, Gregory; Cutler, Richard; Kumar, Pavan; MacKenzie, Crystal; Lin, Charles; DiMartino, Jorge; Olek, Elizabeth; Van Tine, Brian
Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)
CANCER RESEARCH
IF16.6
2024-04-051
PRE
Izar, Benjamin; Zamarin, Dmitriy; Spigel, David R.; Hoimes, Christopher J.; McDermott, David F.; Sehgal, Kartik; Najjar, Yana G.; Schoenfeld, Adam J.; Garon, Edward B.; Sullivan, Ryan J.; Henick, Brian S.; Leal, Ticiana A.; Hurwitz, Michael E.; McKay, Rana R.; Busby, Natalie; Mehta-Damani, Anita; Azrilevich, Alex; Tran, Tony; Rizvi, Naiyer; Oft, Martin; Spira, Alexander I.
A dose escalation and cohort expansion study of the CDK9 inhibitor KB0742 in relapsed, refractory and transcriptionally addicted solid tumors
CANCER RESEARCH
IF16.6
2024-04-050
PRE
Calero, Miguel Villalona; Agulnik, Mark; Mita, Monica; Mita, Alain; Federman, Noah; Rasco, Drew; Spigel, David; Luo, Jia; Hanna, Glenn; Cote, Gregory; Salkeni, Mohamad A.; Chugh, Rashmi; Ammakkanavar, Natraj R.; Shah, Satish A.; Rao, Amol; Sankhala, Kamalesh Kumar; Cutler, Richard E.; Hood, Tressa; Carvajal, Luis; MacKenzie, Crystal; Lin, Charles; DiMartino, Jorge; Olek, Elizabeth A.; Van Tine, Brian
First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data
CANCER RESEARCH
IF16.6
2024-04-050
PRE
Van Tine, Brian A.; Ahn, Eugene; Redman, Rebecca A.; Barve, Minal A.; Edenfield, William J.; Peguero, Julio; Villaflor, Victoria M.; Rasco, Drew W.; Powell, Steven F.; Mamuye, Admasu T.; Moore, Chris B.; Pelham, Joshua M.; Charoenthongtrakul, Soratree; Spigel, David R.
Tumor informed circulating tumor DNA monitoring for early treatment response and survival outcomes on trastuzumab plus pertuzumab
CANCER RESEARCH
IF16.6
2024-03-220
PRE
Kurzrock, Razelle; Childress, Merrida; Li, Wenshu; Muse, Anna; Malato, Julia; Wang, Yong; Liu, Minetta; Aleshin, Alexey; Wang, Richard S.; Thierauf, Julia; Sweeney, Christopher J.; Hainsworth, John; Szado, Tania; Young, Amanda; Schulze, Katja; Spigel, David; Meric-Bernstam, Funda; Swanton, Charles; Burris, Howard A.
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2024-03-1313
OAAI
Lenz, Heinz-Josef; Parikh, Aparna; Spigel, David R.; Cohn, Allen L.; Yoshino, Takayuki; Kochenderfer, Mark; Elez, Elena; Shao, Spencer H.; Deming, Dustin; Holdridge, Regan; Larson, Timothy; Chen, Eric; Mahipal, Amit; Ucar, Antonio; Cullen, Dana; Baskin-Bey, Edwina; Kang, Tong; Hammell, Amy B.; Yao, Jin; Tabernero, Josep
A dose escalation and cohort expansion study of the CDK9 inhibitor KB0742 in relapsed, refractory ovarian cancer and transcriptionally addicted relapsed or refractory solid tumors
CANCER RESEARCH
IF16.6
2024-03-040
PRE
Villalona-Calero, Miguel; Mita, Monica; Mita, Alain; Federman, Noah; Rasco, Drew; Spigel, David; Luo, Jia; Cote, Gregory M.; Cutler, Richard E.; Kumar, Pavan; MacKenzie, Crystal J.; Lin, Charles; DiMartino, Jorge F.; Olek, Elizabeth A.; Van Tine, Brian

Research Directions

The data has not been retrieved yet.
H
Howard A. Burris
H-index:117Papers:1,141Citations:7.1万
J
John D. Hainsworth
H-index:98Papers:791Citations:5.7万
L
Luis Paz‐Ares
H-index:116Papers:1,392Citations:9.3万
S
Suzanne F. Jones
H-index:46Papers:302Citations:1.0万
F
F. Anthony Greco
H-index:75Papers:636Citations:2.1万
M
Martin Reck
H-index:88Papers:630Citations:5.2万
E
Enriqueta Felip
H-index:129Papers:1,499Citations:11.0万
S
Scott Antonia
H-index:93Papers:542Citations:7.6万
G
Ganesh Mugundu
H-index:19Papers:94Citations:1,193
D
Davey B. Daniel
H-index:28Papers:134Citations:1.3万